[{"id":"31d6ffe2-4ba8-4867-90e7-d162923e570c","acronym":"Lung-MAP","url":"https://clinicaltrials.gov/study/NCT02154490","created_at":"2021-01-18T06:59:07.141Z","updated_at":"2024-07-02T16:35:46.669Z","phase":"","brief_title":"Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer","source_id_and_acronym":"NCT02154490 - Lung-MAP","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • ALK • EML4 • TP63","pipe":" | ","alterations":" EGFR mutation • ALK fusion • TTF1 negative","tags":["EGFR • ALK • EML4 • TP63"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • TTF1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Talzenna (talazoparib) • Imjudo (tremelimumab-actl) • fexagratinib (ABSK091) • taselisib (GDC-0032) • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 1864","initiation":"Initiation: 07/08/2014","start_date":" 07/08/2014","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 04/15/2022","study_completion_date":" 04/15/2022","last_update_posted":"2023-06-01"},{"id":"2659c88d-8ccf-419b-9c5d-c230bd257702","acronym":"MEGA","url":"https://clinicaltrials.gov/study/NCT01443065","created_at":"2021-01-18T05:58:59.318Z","updated_at":"2024-07-02T16:36:38.614Z","phase":"Phase 2","brief_title":"MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma","source_id_and_acronym":"NCT01443065 - MEGA","lead_sponsor":"UNICANCER","biomarkers":" MET","pipe":"","alterations":" ","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 162","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 09/01/2018","study_completion_date":" 09/01/2018","last_update_posted":"2020-11-17"},{"id":"77b0d6cb-b2a1-4125-84de-5c4dfb52ec94","acronym":"","url":"https://clinicaltrials.gov/study/NCT01233687","created_at":"2021-01-18T04:57:38.676Z","updated_at":"2024-07-02T16:37:20.771Z","phase":"Phase 1/2","brief_title":"AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01233687","lead_sponsor":"Ahmad Tarhini","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • rilotumumab (AMG 102)"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 08/01/2011","start_date":" 08/01/2011","primary_txt":" Primary completion: 11/01/2014","primary_completion_date":" 11/01/2014","study_txt":" Completion: 11/01/2014","study_completion_date":" 11/01/2014","last_update_posted":"2017-06-22"}]